Nubeqa and Rosuvastatin Tablets
Determining the interaction of Nubeqa and Rosuvastatin Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with darolutamide may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is darolutamide inhibition of intestinal and hepatobiliary efflux of rosuvastatin via breast cancer resistance protein (BCRP). When rosuvastatin, a known BCRP substrate, was administered concomitantly with darolutamide, mean rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 5-fold. High levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. MANAGEMENT: Concomitant use of rosuvastatin with darolutamide should generally be avoided. If coadministration is required, the lowest effective dosage of rosuvastatin should be used and close monitoring for musculoskeletal toxicity is recommended. Alternatively, a different HMG-CoA reductase inhibitor that is not a substrate for BCRP may be considered. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. References "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Professional:GENERALLY AVOID: Coadministration with darolutamide may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is darolutamide inhibition of intestinal and hepatobiliary efflux of rosuvastatin via breast cancer resistance protein (BCRP). When rosuvastatin, a known BCRP substrate, was administered concomitantly with darolutamide, mean rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 5-fold. High levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.
MANAGEMENT: Concomitant use of rosuvastatin with darolutamide should generally be avoided. If coadministration is required, the lowest effective dosage of rosuvastatin should be used and close monitoring for musculoskeletal toxicity is recommended. Alternatively, a different HMG-CoA reductase inhibitor that is not a substrate for BCRP may be considered. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.
- "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Generic Name: rosuvastatin
Brand name: Crestor, Ezallor Sprinkle
Synonyms: Rosuvastatin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Nubeqa-Rotarix
- Nubeqa-Rotateq
- Nubeqa-Rotavirus Oral Vaccine
- Nubeqa-Rotavirus Vaccine
- Nubeqa-Rotavirus Vaccine Live Oral
- Nubeqa-Rotavirus vaccine, live
- Rosuvastatin Tablets-Nucofed Pediatric Expectorant
- Rosuvastatin Tablets-NuCort
- Rosuvastatin Tablets-NuCort Lotion
- Rosuvastatin Tablets-Nucynta
- Rosuvastatin Tablets-Nucynta ER
- Rosuvastatin Tablets-Nucynta Solution